Patent SG-11201900344Y-A (SG)
Title: Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
Inventor: GILL SAAR
IPC: A61K35/17
Filed: 2017-07-14
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 0111111 011111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0 WO 2018/013918 A2 18 January 2018 (18.01.2018) W I PO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/00 (2006.01) A61K 35/17 (2015.01) KM, ML, MR, NE, SN, TD, TG). A61K 35/00 (2006.01) (21) International Application Number: Published: PCT/US2017/042129 — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (22) International Filing Date: 14 July 2017 (14.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/362,659 15 July 2016 (15.07.2016) US 62/366,997 26 July 2016 (26.07.2016) US 62/381,230 30 August 2016 (30.08.2016) US (71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). Inventors; and (72) = (71) Applicants: GILL, Saar [US/US]; 30 North 3rd Street, Apt. 4A, Philadelphia, PA 19106 (US). KENDERIAN, Saad [US/US]; 103 Surgeon Generals Ct, Philadelphia, PA = — 19146 (US). RUELLA, Marco [IT/US]; 500 S. 47th Street, Apt. 302, Philadelphia, PA 19143 (US). = Agent: COLLAZO, Diana M. et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, (74) _ Cambridge, MA 02142 (US). = = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, _ = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, — HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = — TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — ei .4 GC 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 01 M 1-1 ......_ © (54) Title: TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RE- GO\" CEPTOR IN COMBINATION WITH A KINASE INHIBITOR 1-1 0> (57) : The disclosure provides compositions and methods for treating diseases associated with expression of an antigen or for \" treating or prevent cytokine release syndrome, e.g., by administering a CAR therapy with a kinase inhibitor, e.g., JAK-STAT inhibitor 0 and/or BTK inhibitor.